Merck Sharp + Dohme Corp.

Sarah Geers

Craig A McKelvey

Dina Zhang

Justin Moser

Sutthilug Sotthivirat

Bhagwant Rege

Michael Lowinger

Robert F Meyer

Craig A Mckelvey

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol. 

Polymer formulations of CETP inhibitors

Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

CB-1 receptor modulator formulations

Growing community of inventors

Weehawken, NJ, United States of America

Sarah Geers